| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2014 | Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer | Lee, Jih-Hsiang; Lin, Yu-Lin; Hsu, Wei-Hsun; Chen, Hsuan-Yu; Chang, Yeun-Chung; Yu, Chong-Jen; Shih, Jin-Yuan; Lin, Chia-Chi; Chen, Kuan-Yu; Ho, Chao-Chi; Laio, Wei-Yu; Yang, Pan-Chyr; Yang, James Chih-Hsin | J. Thorac. Oncol. | | | |
| 2014 | Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer | Lee, Jih-Hsiang; Lin, Yu-Lin; Hsu, Wei-Hsun; Chen, Hsuan-Yu; Chang, Yeun-Chung; Yu, Chong-Jen; Shih, Jin-Yuan; Lin, Chia-Chi; Chen, Kuan-Yu; Ho, Chao-Chi; Laio, Wei-Yu; Yang, Pan-Chyr; Yang, James Chih-Hsin; 楊泮池 | J. Thorac. Oncol. | | | |
| 2009 | Bibw 2992, a Novel Irreversible Egfr/Her2 Tyrosine Kinase Inhibitor, in Chemonaive Patients with Adenocarcinoma of the Lung and Activating Egfr Mutations | YANG, CHIH-HSIN; SHIH, JIN-YUAN | JOURNAL OF THORACIC ONCOLOGY | | | |
| 2008 | Effects of activating epidermal growth factor receptor mutations on clinical response | Gow, Chien-Hung; Chien, Chun-Ru; Chang, Yih-Leong; Chiu, Yueh-Hsai; Kuo, Sung-Hsin; Shih, Jin-Yuan; Chang, Yeun-Chung; Yu, Chong-Jen; Yang, Chih-Hsin; Yang, Pan-Chyr | Clin Cancer Res | | | |
| 2005 | Egfr Mutation Conferring Primary Resistance to Gefitinib in Non–Small- Cell Lung Cancer | YANG, PAN-CHYR; GOW, CHIEN-HUNG; SHIH, JIN-YUAN; 楊泮池 | THE NEW ENGLAND JOURNAL OF MEDICINE | | | |
| 2015 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis. | Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2015 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis. | Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2008 | First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. | Wu, Jenn-Yu; Yu, Chong-Jen; Chih-HsinYang; Wu, Shang-Gin; Chiu, Yueh-Hsia; Gow, Chien-Hung; Chang, Yeun-Chung; Hsu, Ya-Chieh; Wei, Pin-Fei; Shih, Jin-Yuan; Yang, Pan-Chyr | American journal of respiratory and critical care medicine | | | |
| 2022 | Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes | Chang, Hao-Chun; Chen, Kuan-Yu; YIH-LEONG CHANG ; Shih, Jin-Yuan; Yu, Chong-Jen | Journal of the Formosan Medical Association = Taiwan yi zhi | | | |
| 2015 | Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial). | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
| 2015 | Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial). | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan | J. Clin. Oncol. | | | |
| 2015 | Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR Mutation | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin | J. Thorac. Oncol. | | | |
| 2015 | Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR Mutation | Tsai, Chun-Ming; Lai, Chun-Liang; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan | J. Thorac. Oncol. | | | |
| 2013 | Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer | Liao, Wei-Yu; Chen, Jin-Hsin; Wu, Muzo; Shih, Jin-Yuan; Chen, Kuan-Yuh; Ho, Chao-Chi; Yang, James Chih-Hsin; Yu, Chong-Jen | Clin. Lung Cancer | | |  |
| 2008 | Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemonaive NSCLC patients receiving first-line gefitinib monotherapy | Yang, Chih-Hsin; Yu, Chong-Jen; Shih, Jin-Yuan; Chang, Yeun-Chung; Hu, Fu-Chang; Tsai, Meng-Chin; Chen, Kuan-Yu; Lin, Zhong-Zhe; Huang, Ching-Ju; Shun, Chia-Tung; Huang, Chin-Lun; Bean, James; Cheng, Ann-Lii; Pao, William; Yang, Pan-Chyr | J Clin Oncol | | | |
| 2023 | Xenon-Enhanced Ventilation Computed Tomography for Functional Lung Avoidance Radiation Therapy in Patients With Lung Cancer | YU-SEN HUANG ; Chen, Jenny Ling-Yu; Lan, Hao-Ting; Tai, Mei-Hwa; SUNG-HSIN KUO ; Shih, Jin-Yuan; Chang, Yeun-Chung | International journal of radiation oncology, biology, physics | 0 | | |
